Loading clinical trials...
Loading clinical trials...
Reducing Hypoglycemic, Pro-coagulant and Pro-atherothrombotic Responses and Preventing Hypoglycemia Associated Autonomic Failure in Type 1 DM. The Effects of Glucagon-like Peptide-1
Conditions
Interventions
Glucagon-like peptide-1
Placebos
Locations
1
United States
University of Maryland
Baltimore, Maryland, United States
Start Date
June 24, 2020
Primary Completion Date
September 24, 2025
Completion Date
September 24, 2025
Last Updated
November 10, 2025
NCT03648918
NCT05777330
NCT03811470
NCT07319286
NCT03582956
NCT03623113
Lead Sponsor
University of Maryland, Baltimore
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions